HoLEP using a 21 Fr internal urethrotomy sheath, a feasible alternative to MiLEP in resource-limited settings
Abstract
Holmium laser enucleation of the prostate (HoLEP) is an effective, size-independent surgical treatment for benign prostatic hyperplasia; however, the use of large-caliber resectoscope sheaths may increase urethral trauma. Dedicated minimally invasive laser enucleation of the prostate (MiLEP) systems aim to reduce this risk but are not universally available. This study aimed to evaluate whether a modified HoLEP technique using a 21 Fr internal urethrotomy sheath (mLC-HoLEP) technique performed with commonly available endourological instruments provides comparable short-term functional and safety outcomes to conventional HoLEP in settings without access to dedicated MiLEP systems. This single-center retrospective cohort study included patients who underwent standard HoLEP (n = 48) or mLC-HoLEP (n = 47) between January 2021 and May 2023. The mLC-HoLEP technique utilized a 21 Fr internal urethrotomy sheath combined with passive bladder drainage via a 16 G suprapubic cannula, followed by standard morcellation with a 26 Fr morcelloscope. Groups were matched using propensity score matching. Perioperative parameters, functional outcomes (IPSS, Qmax, postvoid residual urine), irrigation volume, and early postoperative complications were compared. Baseline demographic and preoperative characteristics were comparable between groups. Operative time, enucleation time, morcellation time, hemoglobin drop, and specimen weight showed no significant differences. Total irrigation volume was…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 48 participants or records.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.